85岁及以上高龄COVID-19患者76例临床特征与死亡风险因素的前瞻性队列研究
该前瞻性队列纳入法国一家大学医院非重症病房收治的76例85岁及以上确诊COVID-19患者,随访21天。常见症状为乏力、发热和意识模糊/谵妄,21天病死率28.9%,入院时C反应蛋白水平和淋巴细胞最低计数为独立死亡预测因素。
要点
- 高龄COVID-19患者常见乏力、发热和谵妄,初始跌倒和消化道症状也不少见。
- 该队列21天病死率为28.9%,并发症包括急性呼吸综合征、心功能失代偿和低血压休克。
- 入院时C反应蛋白水平和淋巴细胞最低计数是死亡的独立预测因素。
核心结论
- 85岁及以上COVID-19患者具有特定临床特征、多器官损伤和高病死率,但快速诊断、适当治疗和监测似乎可改善预后。
研究设计与样本
- 前瞻性队列研究,纳入2020年3月14日至4月11日在法国巴黎Lariboisière Fernand-Widal大学医院非重症病房住院的85岁及以上确诊SARS-CoV-2感染患者76例,随访21天。
主要发现
- 患者中位年龄90(86-92)岁,女性占55.3%,64.5%有三种及以上合并症。
- 最常见症状为乏力(76.3%)、发热(75.0%)和意识模糊及谵妄(71.1%),初始跌倒占25.0%,消化道症状占22.4%。
- COVID-19严重程度:重度51.3%、中度32.9%、轻度15.8%;并发症包括急性呼吸综合征(28.9%)、心功能失代偿(14.5%)和低血压休克(9.0%)。
- 21天病死率为28.9%,中位病程13(8-17)天;死亡者中男性占68.2%;幸存者中位住院时间12(9-19.5)天。
- 独立死亡预测因素为入院时C反应蛋白水平和淋巴细胞最低计数。
临床怎么用
- 对85岁及以上COVID-19患者应警惕乏力、谵妄、跌倒和消化道症状等不典型表现。
- 入院时关注C反应蛋白水平和淋巴细胞最低计数,有助于识别死亡高风险患者。
- 对高龄患者实施快速诊断、适当治疗和监测可能改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical presentation and risk factors of death in COVID-19 in oldest adults have not been well characterized. OBJECTIVES: To describe clinical features and outcome of COVID-19 in patients older than 85 years and study risk factors for mortality. DESIGN: Prospective cohort. PARTICIPANTS AND SETTING: Patients aged 85 years and older, admitted in noncritical care units at the University Hospital Lariboisière Fernand-Widal (Paris, France) for confirmed severe acute respiratory syndrome coronavirus 2 infection were included and followed up for 21 days. MEASUREMENTS: Clinical and laboratory findings were collected. Cox survival analysis was performed to explore factors associated with death. RESULTS: From March 14 to April 11, 2020, 76 patients (median age = 90 (86-92) years; women = 55.3%) were admitted for confirmed COVID-19. Of the patients, 64.5% presented with three or more comorbidities. Most common symptoms were asthenia (76.3%), fever (75.0%) and confusion and delirium (71.1%). An initial fall was reported in 25.0% of cases, and digestive symptoms were reported in 22.4% of cases. COVID-19 was severe in 51.3% of cases, moderate in 32.9%, and mild in 15.8%. Complications included acute respiratory syndrome (28.9%), cardiac decompensation (14.5%), and hypotensive shock (9.0%). Fatality at 21 days was 28.9%, after a median course of disease of 13 (8-17) days. Males were overrepresented in nonsurvivors (68.2%). In survivors, median length of stay was 12 (9-19.5) days. Independent predictive factors of death were C-reactive protein level at admission and lymphocyte count at nadir. CONCLUSION: Specific clinical features, multiorgan injury, and high case fatality rate are observed in older adults with COVID-19. However, rapid diagnosis, appropriate care, and monitoring seem to improve prognosis.
引用
- Vrillon A, Hourregue C, Azuar J, et al. COVID-19 in Older Adults: A Series of 76 Patients Aged 85 Years and Older with COVID-19. J Am Geriatr Soc. 2020. PMID: 33045106. doi:10.1111/jgs.16894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。